Where is Restem located?

Restem is headquartered in Corona, United States.

How many employees does Restem have?

As of Jul 31, 2026, the latest employee count at Restem is 23.

Where does Restem rank among its competitors?

Restem ranks 71st amongst 386 active competitors, of which 134 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Evommune, which secured $125M in Feb, 2026.

Who are the top competitors of Restem?

Restem's top competitors include Tenaya Therapeutics, Evommune and Upstream Bio. Among them, Evommune secured the most recent funding round in February, 2026.

Restem - 2026 Company Profile, Team & Competitors

Restem is an unfunded company based in Corona (United States), founded in 2016 by Rafael Gonzalez. It operates as a Developer of cell-based therapeutics to treat inflammatory-driven diseases. Restem has not raised any funding yet. The company has 386 active competitors, including 134 funded and 79 that have exited. Its top competitors include companies like Tenaya Therapeutics, Evommune and Upstream Bio.

Company Details

Developer of cell-based therapeutics to treat inflammatory-driven diseases. The company is focused on developing off-the-shelf cell therapies to modulate the immune system and treat inflammatory, autoimmune, and age-related diseases.

Website: restem.com
Email ID: *****@restem.com
Phone Number: +1 **********

Key Metrics

Founded Year

2016

Location

Corona, United States

Stage

Unfunded

Ranked

71^st among 386 active competitors

Employee Count

23 as on Jul 31, 2026

Investment & Acquisitions

Diakonos

Similar Companies

Tenaya Therapeutics & 469 more

View Restem's full profile

Restem has not raised any funding rounds yet.

The founders of Restem is Rafael Gonzalez. David Pyrce is the CEO of Restem.

Here are the details of Restem's key team members:

Rafael Gonzalez: Founder of Restem.
Contact Info: 1 email address
David Pyrce: CEO of Restem.

View details of Restem's Founder profiles and Board Members

Restem's employee count trend

Restem has 23 employees as of Jul 26. Here is Restem's employee count trend over the years:

Uncover Restem's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Restem include Tenaya Therapeutics, Evommune and Upstream Bio. Here is the list of Top 10 competitors of Restem, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Tenaya Therapeutics 2016, San Francisco (United States), Public	Developer of regenerative and gene therapeutics for heart failure	$248M	RTW Investments, Fidelity Investments & 7 others	70/100
2nd	Evommune 2020, Sacramento (United States), Public	Developer of therapeutic options for chronic inflammatory disorders	$276M	Pivotal bioVenture Partners, Sectoral & 18 others	69/100
3rd	Upstream Bio 2021, Waltham (United States), Public	Developer of therapeutics for allergic and inflammatory diseases	$400M	Venrock, Orbimed & 11 others	67/100
4th	Odyssey 2018, Cambridge (United States), Public	Developer of immunotherapeutics for immunological and cancer diseases	$717M	Orbimed, Ascenta Capital & 29 others	66/100
5th	Septerna 2020, San Bruno (United States), Public	Developer of GPCR drug discovery platform for multiple diseases	$250M	RA Capital Management, Third Rock Ventures ... & 14 others	66/100
6th	Ventyx Biosciences 2018, Encinitas (United States), Acquired	Developer of therapeutics to treat autoimmune diseases	$165M	VenBio, Logos Capital & 13 others	66/100
7th	CalciMedica 2006, San Diego (United States), Public	Developer of CRAC channel inhibitor drugs for inflammatory diseases	$76.7M	Biogen, SR One & 11 others	64/100
8th	Tune Therapeutics 2009, Seattle (United States), Series B	Developer of cell and gene therapy by using the epigenomic platform	$222M	New Enterprise Associates, Emerson Collective ... & 8 others	63/100
9th	Orca Bio 2016, Menlo Park (United States), Series F	Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders	$300M	Lightspeed Venture Partners, Mubadala & 11 others	63/100
10th	Inotrem 2013, Paris (France), Series B	Developer of peptide immunotherapies for treating septic shock and acute myocardial infarction	$122M	Morningside, Morningside & 11 others	62/100
71st	Restem 2016, Corona (United States), Unfunded	Developer of cell-based therapeutics to treat inflammatory-driven diseases	-	-	47/100